Deep Phenotyping of the Renal Allograft to Prognosticate Clinical Outcomes

Conditions

• Renal Transplant Rejection

Eligibility Criteria

Sex

ALL

Age

18 Years - N/A

Healthy Volunteers

Not accepted

Study Details

The goal of this observational study is to determine phenotypic, transcriptional, and epigenetic underpinnings of renal allograft rejection in renal transplant rejection. The main questions it aims to answer are: * To determine the phenotype, frequency, location, and the inter-cellular interactions between the cells that constitute intra-graft inflammatory infiltrate in acute ejection. * To determine the phenotype, frequency, location, and the inter-cellular interactions between the cells that constitute intra-graft inflammatory infiltrate in recurrent/recalcitrant rejection vs. rejection that resolves with therapy. * To generate a scRNA sequencing (scRNAseq) map of the intra-graft immune cells and the renal parenchymal cells and compare the transcriptional and epigenetic changes within these cells in recurrent/recalcitrant rejection vs. rejection that resolves with therapy. * To determine phenotypic changes associated with chronic rejection. Participants will be asked to provide the following research specimens: * Renal biopsy specimens at the following timepoints: day of transplantation (pre-implantation and post-perfusion); routine protocol biopsies at 3 months and 12 months; and clinically indicated for-cause biopsies at any timepoint from time-0 to 1-yr post-transplantation. The 1st research core will be used for routine histopathological examination and left over tissue from this core will be used for deep phenotyping using multiparameter immunophenotyping, and digital spatial profiling. The second research core will be used for extraction of cells and nuclei for scRNAseq and snATACseq. * Blood samples will be processed to obtain plasma (for cytokine, chemokine and DSA measurements) and PBMC (for deep phenotyping and molecular analyses). For each collection timepoint, up to 75 mL (about 5 tablespoons) will be collected. * Prospective clinical data and outcomes will be collected from participant medical records. * Follow-Up Period: For-cause biopsies from 1-yr to 5-yr post-transplantation (by the transplant nephrologist): no additional cores will be obtained for research from these biopsies. The left-over tissue from the clinically indicated biopsy cores will be analyzed by deep phenotyping and digital spatial profiling. Blood samples will be processed to obtain plasma (for cytokine, chemokine and DSA measurements) and PBMC (for deep phenotyping and molecular analyses).

Key Dates

Start date

Apr 30, 2026

Status verified

Dec 2025

Primary completion

Dec 31, 2027

Completion

Jul 31, 2030

Study Design

Enrollment

24 participants (estimated)

Arms

• Arm: Renal transplantation recipients
  Living donor and deceased donor renal transplant recipients. There is no intervention to be administered.

Primary Outcome Measure

Percentage of Participants with Biopsy Proven Acute Rejection at one year [ Time Frame: 1 year ]

Central Contacts

• Beth Elinoff, RN
  412-624-6611
  [email protected]
• Aravind Cherukuri, MD
  4125250671
  [email protected]

Locations (1)

Find similar trials in Pittsburgh, PA

Related Studies

• Multi-Parametric MRI for Renal Transplantation
  Not Yet Recruiting · University of Minnesota · Minneapolis, Minnesota
• Study of Combined Kidney and Blood Stem Cell Transplant From a Brother or Sister Donor
  PHASE1/PHASE2 · Recruiting · Jeffrey Veale, MD · Los Angeles, California